Overall, this case highlights the favorable clinical activity of T-DXd in managing HER2-low advanced breast cancer while underscoring the challenges of balancing efficacy and toxicity—particularly ILD—among elderly patients with multiple comorbidities. Here, ERBB2 is linked to breast cancer.